Pasi A Janne

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
    J P Koivunen
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Cancer 99:245-52. 2008
  2. ncbi request reprint Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    Pasi A Janne
    Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 14:38-47. 2013
  3. pmc Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial
    Pasi A Janne
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 30:2063-9. 2012
  4. ncbi request reprint Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, D1234 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:3227-34. 2005
  5. ncbi request reprint Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    Semin Oncol 32:S9-15. 2005
  6. ncbi request reprint A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:751-8. 2006
  7. ncbi request reprint Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4416s-4420s. 2006
  8. ncbi request reprint Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 25:3936-44. 2007
  9. pmc Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1131-9. 2011
  10. doi request reprint Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma
    Pasi A Janne
    Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA
    J Clin Oncol 26:1465-71. 2008

Detail Information

Publications103 found, 100 shown here

  1. pmc Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
    J P Koivunen
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Cancer 99:245-52. 2008
    ..002). The outcome of stages I and II NSCLC patients treated with surgery alone did not significantly differ based on LKB1 mutation status. Our study provides clinical and molecular characteristics of NSCLC, which harbour LKB1 mutations...
  2. ncbi request reprint Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    Pasi A Janne
    Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 14:38-47. 2013
    ..We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC...
  3. pmc Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial
    Pasi A Janne
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 30:2063-9. 2012
    ..We investigated the efficacy of erlotinib alone or in combination with chemotherapy in patients with these characteristics...
  4. ncbi request reprint Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, D1234 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:3227-34. 2005
    ..The frequency of EGFR mutations, their impact on NSCLC biology, clinical treatment, and clinical trial design, as well as methods and limitations for mutation detection, will be reviewed...
  5. ncbi request reprint Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    Semin Oncol 32:S9-15. 2005
    ..The rationale and design of these trials will be reviewed...
  6. ncbi request reprint A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:751-8. 2006
    ..Here we describe the use of a sensitive screening method that overcomes many of these limitations...
  7. ncbi request reprint Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4416s-4420s. 2006
    ..These approaches are being studied in ongoing clinical trials and will spur the development of additional technology for EGFR mutation detection...
  8. ncbi request reprint Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 25:3936-44. 2007
    ..To evaluate the efficacy of the pan-ERBB inhibitor, CI-1033, in platinum-refractory or recurrent advanced-stage non-small-cell lung cancer (NSCLC)...
  9. pmc Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1131-9. 2011
    ..This first-in-human study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF299804 in patients with advanced solid malignancies...
  10. doi request reprint Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma
    Pasi A Janne
    Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA
    J Clin Oncol 26:1465-71. 2008
    ..Pemetrexed and gemcitabine have single-agent activity in malignant pleural mesothelioma (MPM). The combination of pemetrexed/gemcitabine has not previously been studied in MPM to our knowledge...
  11. ncbi request reprint Patterns of failure following surgical resection for malignant pleural mesothelioma
    Pasi A Janne
    Harvard Medical School, Boston, MA 02115, USA
    Thorac Surg Clin 14:567-73. 2004
    ..The appropriate multimodality approaches most likely will differ based on disease stage, histology, and patient performance status. intrapleural chemotheraphy treatments. These two For Patients who have undergone EPP, the pattern..
  12. ncbi request reprint Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1234, Boston, MA 02115, USA
    Lung Cancer 44:221-30. 2004
    ....
  13. ncbi request reprint The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma
    Pasi A Janne
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, USA
    Ann Med 35:450-7. 2003
    ..This article will review the pre-clinical rationale and the clinical studies of EGFR inhibitors alone and/or in combination with chemotherapy that have been performed to date in advanced NSCLC...
  14. ncbi request reprint [Gefitinib therapy in non-small-cell lung cancer]
    Pasi A Janne
    Harvard Medical School, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Duodecim 121:249-51. 2005
  15. ncbi request reprint Chemotherapy for malignant pleural mesothelioma
    Pasi A Janne
    Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lung Cancer 5:98-106. 2003
    ..Orally available small molecule inhibitors of several receptor tyrosine kinases have been developed and are now being evaluated in clinical trials...
  16. ncbi request reprint Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 62:5242-7. 2002
    ..Our findings demonstrate that in vitro, ZD1839 is as effective or more effective against MPM cell lines as it is against the NSCLC cell line A549 and suggest that ZD1839 may be an effective therapeutic option for patients with MPM...
  17. pmc Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Clin Invest 116:2695-706. 2006
    ....
  18. ncbi request reprint Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 97:1185-94. 2005
    ..However, little is known about the efficacy of cetuximab, an antibody against the EGFR extracellular domain, in EGFR mutant NSCLC...
  19. ncbi request reprint The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:485-95. 2006
    ..These data suggest that persistent EGFR signaling is required for tumor maintenance in human lung adenocarcinomas expressing EGFR mutants...
  20. ncbi request reprint Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
    Sean Tracy
    Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 64:7241-4. 2004
    ..These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib...
  21. ncbi request reprint Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    ..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib...
  22. pmc Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
    Alexa B Turke
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Cancer Cell 17:77-88. 2010
    ..These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy...
  23. pmc ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
    Jeffrey A Engelman
    Department of Systems Biology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 102:3788-93. 2005
    ..We conclude that ErbB-3 is used to couple EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines harboring WT and mutant EGFRs...
  24. ncbi request reprint Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Oncol 1:506-12. 2006
    ..To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP)...
  25. ncbi request reprint Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:1698-704. 2003
    ..To determine the maximum-tolerated dose of docetaxel (DOC) in combination with carboplatin (CAR) and thoracic radiotherapy (RT), in the setting of trimodality treatment of patients with stage III non-small cell lung cancer (NSCLC)...
  26. ncbi request reprint Inhibition of the met receptor in mesothelioma
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:8122-30. 2005
    ..HGF stimulation has been shown to enhance MPM cell proliferation, migration, cell scattering, and invasiveness...
  27. doi request reprint Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery
    Hale B Caglar
    Department of Radiation Oncology Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Cancer 115:4156-66. 2009
    ..The objective of this study was to identify the factors associated with improved outcome after treatment for stage III nonsmall cell lung cancer (NSCLC)...
  28. ncbi request reprint Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:760-6. 2007
    ..The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement...
  29. pmc Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts
    Cancer 119:3761-8. 2013
    ....
  30. pmc Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR
    Qingsong Liu
    Department of Cancer Biology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA, USA
    Cancer Res 73:2574-86. 2013
    ..Taken together, our findings establish Torin2 as a strong candidate for clinical evaluation in a broad number of oncologic settings where mTOR signaling has a pathogenic role...
  31. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  32. pmc Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers
    Kimio Yonesaka
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:6963-73. 2008
    ..The determinant(s) of efficacy of EGFR-targeted therapies in EGFR wild-type cancers is not well defined...
  33. ncbi request reprint LKB1 modulates lung cancer differentiation and metastasis
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 448:807-10. 2007
    ..These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis...
  34. pmc Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
    David M Jackman
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5267-73. 2009
    ....
  35. pmc RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0
    Mizuki Nishino
    Department of Imaging Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston MA 02215, USA
    AJR Am J Roentgenol 201:W64-71. 2013
    ..The impact of RECIST 1.1 was compared with RECIST 1.0 in non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors...
  36. ncbi request reprint Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
    Xiaojun Zhao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:5561-70. 2005
    ..EGFR amplification was shown to be independent of kinase domain mutational status...
  37. pmc Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers
    Lynette M Sholl
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 69:8341-8. 2009
    ..In these cases, EGFR amplification is heterogeneously distributed, mostly in areas with a solid histology...
  38. ncbi request reprint EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..These results suggest that EGFR mutations may predict sensitivity to gefitinib...
  39. ncbi request reprint Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
    David M Jackman
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:808-14. 2008
    ..These agents have activity in non-small cell lung cancer, but their role in mesothelioma is unclear. The primary endpoint is response rate. Secondary endpoints include time to progression, survival, and toxicity...
  40. pmc New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
    AJR Am J Roentgenol 195:W221-8. 2010
    ..1) to the original guidelines (RECIST 1.0) for advanced non-small cell lung cancer (NSCLC) after erlotinib therapy and to evaluate the impact of the new CT tumor measurement guideline on response assessment...
  41. pmc Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7060-7. 2008
    ..Our goal was to determine the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib...
  42. ncbi request reprint Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School Partners Healthcare Center for Genetics and Genomics, MGH Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Oncologist 12:90-8. 2007
    ..6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information...
  43. doi request reprint First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
    ..The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms...
  44. pmc Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 79:283-8. 2013
    ..TKIs are often continued beyond progressive disease by RECIST. We investigated the practice of continuing EGFR-TKIs after RECIST-PD via CT findings...
  45. ncbi request reprint Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
    Jingrui Jiang
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:8968-74. 2005
    ..Our results provide a model system to study the function of mutated EGFR and the differential effects of pharmacologic EGFR inhibition on the distinct mutant forms of this tyrosine kinase...
  46. ncbi request reprint Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    David M Jackman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:4517-20. 2006
  47. ncbi request reprint Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma
    William G Richards
    Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 24:1561-7. 2006
    ..To evaluate morbidity, mortality, maximum-tolerated dose (MTD), and outcome of intraoperative intracavitary hyperthermic cisplatin lavage in patients undergoing pleurectomy for malignant pleural mesothelioma (MPM)...
  48. ncbi request reprint An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays
    Xiaojun Zhao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 64:3060-71. 2004
    ..The simultaneous measurement of DNA copy number changes and loss of heterozygosity events by SNP arrays should strengthen our ability to discover cancer-causing genes and to refine cancer diagnosis...
  49. ncbi request reprint PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    ..These preclinical evaluations support further clinical development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members...
  50. pmc Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer
    Yanan Kuang
    Translational Research Laboratory, Center for Clinical and Translational Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:2630-6. 2009
    ..As most patients do not undergo repeated tumor biopsies we evaluated whether EGFR T790M could be detected using plasma DNA...
  51. ncbi request reprint EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    ..Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance...
  52. ncbi request reprint MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well...
  53. pmc Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer
    Stephanie Cardarella
    Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 19:4532-40. 2013
    ..BRAF mutations are found in a subset of non-small cell lung cancers (NSCLC). We examined the clinical characteristics and treatment outcomes of patients with NSCLC harboring BRAF mutations...
  54. ncbi request reprint Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology 68:500-10. 2005
    ..Furthermore, combinations of growth factor and signal transduction inhibitors may be needed to inhibit the growth of the majority of MPM cell lines, and therefore patients with MPM...
  55. pmc ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas
    Lynette M Sholl
    Department of Pathology, Brigham and Women s Hospital Lowe Center for Thoracic Oncology Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA
    Am J Surg Pathol 37:1441-9. 2013
    ..ROS1 protein expression in tumor cells is 100% sensitive and 92% specific for ROS1 rearrangements by FISH. ROS1 IHC is an effective screening tool for this rare but clinically important subset of lung ACAs. ..
  56. ncbi request reprint High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncogene 23:2716-26. 2004
    ..Using this array, we identified small regions of LOH that were not detected by lower density SNP arrays or by standard microsatellite marker panels...
  57. pmc A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
    Zhao Chen
    Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 483:613-7. 2012
    ....
  58. pmc Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
    Alexis B Cortot
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 73:834-43. 2013
    ..However, multiple drug resistance mechanisms can still emerge. Preventing the emergence of drug resistance, by targeting pathways that become activated in resistant cancers, may be a more effective clinical strategy...
  59. pmc Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors
    Dalia Ercan
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Discov 2:934-47. 2012
    ..Our findings provide insights into mechanisms of drug resistance to EGFR kinase inhibitors and highlight rational combination therapies that should be evaluated in clinical trials...
  60. ncbi request reprint Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy
    Aaron M Allen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 68:1366-74. 2007
    ..We compared the outcomes after moderate-dose hemithoracic radiotherapy (MDRT) and high-dose hemithoracic RT (HDRT) after EPP for malignant pleural mesothelioma...
  61. pmc The biology and treatment of EML4-ALK non-small cell lung cancer
    Takaaki Sasaki
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 46:1773-80. 2010
    ..This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC...
  62. pmc EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry
    Lynette M Sholl
    Department of Pathology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Am J Clin Pathol 133:922-34. 2010
    ..Thus, EGFR sequence analysis was the only method useful for predicting response and progression-free survival following TKI therapy in NSCLC...
  63. ncbi request reprint Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
    Danan Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 12:81-93. 2007
    ..However, the combination of HKI-272 and rapamycin resulted in significant regression of both types of lung tumors. This combination therapy may potentially benefit lung cancer patients with the EGFR T790M mutation...
  64. pmc Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors
    Jie Qi
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA
    Cancer Res 71:1081-91. 2011
    ..Importantly, these results also underscore the notion that a single cancer can simultaneously develop resistance induced by several mechanisms and highlight the daunting challenges associated with preventing or overcoming resistance...
  65. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
    ..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies...
  66. ncbi request reprint Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Alice T Shaw
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 368:2385-94. 2013
    ..Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown...
  67. pmc The introduction of systematic genomic testing for patients with non-small-cell lung cancer
    Stephanie Cardarella
    Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Thorac Oncol 7:1767-74. 2012
    ..We report the implementation of systematic prospective genotyping for somatic alterations in BRAF, PIK3CA, HER2, and ALK, in addition to EGFR and KRAS, in NSCLC patients at the Dana-Farber Cancer Institute...
  68. pmc Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
    Zhao Chen
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:9827-36. 2010
    ..Taken together, our findings define a murine model that offers a reliable platform for the preclinical comparison of combinatorial treatment approaches for lung cancer characterized by ALK rearrangement...
  69. pmc Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    Wenjun Zhou
    Department of Cancer Biology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 462:1070-4. 2009
    ..Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors...
  70. ncbi request reprint Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    Lecia V Sequist
    Cancer Center and Department of Medicine, Massachusetts General Hospital, and Laboratory for Molecular Medicine, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:4403s-4408s. 2006
    ..It is likely that mutation testing and other molecular analyses will be most useful in these two clinical situations...
  71. pmc Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
    Lu Xu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer Res 72:3302-11. 2012
    ..Our findings therefore provide an in vivo model of intrinsic resistance to reversible TKIs and offer preclinical proof-of-principle that combination targeting of EGFR and MET may benefit patients with NSCLC...
  72. pmc Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer
    Xuemei Yang
    Beth Israel Deaconess Medical Center, Division of Signal Transduction, Boston, Massachusetts 02115, USA
    Cancer Res 71:5965-75. 2011
    ..Using this technique to define the pathways that activate PI3K signaling in a given tumor could help inform clinical decision making by helping guide personalized therapeutic strategies for different patients...
  73. ncbi request reprint Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:s4628-31. 2007
    ..A trial combining erlotinib with everolimus has been undertaken for patients with relapsed NSCLC...
  74. doi request reprint Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lung Cancer 60:S3-9. 2008
    ..In this way, treatment strategies in NSCLC are becoming increasingly tailored to the individual, and may set an example for other areas of oncology...
  75. ncbi request reprint Factors predicting response to EGFR tyrosine kinase inhibitors
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02115, USA
    Semin Respir Crit Care Med 26:314-22. 2005
    ....
  76. pmc EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
    Jussi P Koivunen
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, D820A, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 14:4275-83. 2008
    ..We determined the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines. We also determined whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-containing cell lines in vitro and in vivo...
  77. ncbi request reprint Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer
    Daniel Cho
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 23:235-7. 2005
  78. pmc Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR
    Jin Li
    Department of Radiation Oncology, Divisions of Genomic Stability and DNA Repair, and Medical Physics, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Clin Chem 55:748-56. 2009
    ..We demonstrate that combining COLD-PCR with TaqMan technology provides TaqMan genotyping with the selectivity needed to detect low-level somatic mutations...
  79. doi request reprint A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
    Kwok K Wong
    Dana Farber Cancer Institute, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:2552-8. 2009
    ..The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were determined in patients with advanced solid tumors...
  80. pmc Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
    Peter S Hammerman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Discov 1:78-89. 2011
    ..As dasatinib is already approved for use, these findings could be rapidly translated into clinical trials...
  81. ncbi request reprint Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program
    Pasi A Janne
    Lowe Center for Thoracic Oncolgy, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Lung Cancer 7:40-6. 2005
    ..Before the regulatory approval of pemetrexed, an expanded access program (EAP) provided access to eligible patients with malignant pleural or peritoneal mesothelioma...
  82. doi request reprint Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 14:2895-9. 2008
    ..Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients...
  83. doi request reprint EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
    Jason H Smouse
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer 117:67-72. 2009
    ..Concern over such interference has discouraged testing cytologic samples, but the adequacy of cytologic specimens for EGFR sequencing has not been studied...
  84. pmc Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
    Heidi Greulich
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS Med 2:e313. 2005
    ..The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described...
  85. pmc New strategies for treatment of ALK-rearranged non-small cell lung cancers
    Takaaki Sasaki
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 17:7213-8. 2011
    ..Finally, we discuss the strategies that are underway to clinically overcome acquired drug resistance...
  86. ncbi request reprint Fulminant hepatic failure secondary to erlotinib
    Weitian Liu
    Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 5:917-20. 2007
    ..We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib...
  87. pmc Discovery of selective irreversible inhibitors for EGFR-T790M
    Wenjun Zhou
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, United States
    Bioorg Med Chem Lett 21:638-43. 2011
    ..A representative compound 3i was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays...
  88. pmc Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
    James E Butrynski
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:1727-33. 2010
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  89. doi request reprint Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  90. doi request reprint Treatment of peritoneal mesothelioma in pediatric patients
    Leigh Anne Cioffredi
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:127-9. 2009
    ..Treatment was well tolerated, and three of these patients have achieved long-term survival. The fathers of three of the patients worked in the construction industry and may have been the source of indirect asbestos exposure...
  91. doi request reprint Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer
    Luca Toschi
    Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 14:5941-6. 2008
    ..This review will discuss different strategies of MET inhibition with a specific focus on combination therapeutic approaches...
  92. pmc Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5216-23. 2009
    ..We evaluated the incidence and the characteristics of ALK-rearranged lung adenocarcinomas within the western population and the optimal diagnostic modality to detect ALK rearrangements in routine clinical practice...
  93. ncbi request reprint Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
    Aaron M Allen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:640-5. 2006
    ..To describe the initial experience at Dana-Farber Cancer Institute/Brigham and Women's Hospital with intensity-modulated radiation therapy (IMRT) as adjuvant therapy after extrapleural pneumonectomy (EPP) and adjuvant chemotherapy...
  94. ncbi request reprint Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy
    Lori J Wirth
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Lung Cancer 44:213-20. 2004
    ..To determine the outcome of patients with pulmonary typical and atypical carcinoid tumors treated with chemotherapy with or without radiotherapy...
  95. ncbi request reprint Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:7525-9. 2005
    ....
  96. ncbi request reprint Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
    Pasi A Janne
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Nat Rev Drug Discov 8:709-23. 2009
    ....
  97. ncbi request reprint Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4436s-4440s. 2006
    ..Preclinical xenograft studies have shown efficacy of pertuzumab in treating NSCLC. Therefore, a trial was undertaken for patients with relapsed NSCLC...
  98. ncbi request reprint Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 28:4953-60. 2010
    ..We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC)...
  99. ncbi request reprint High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation
    Harvey J Mamon
    Department of Radiation Oncology and Medical Oncology, Dana Farber Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 23:1530-7. 2005
    ..We sought to review our experience with surgically staged IIIA (N2) non-small-cell lung cancer (NSCLC), focusing on the patterns of failure in consecutively treated patients from 1988 to 2000...
  100. ncbi request reprint Basic treatment considerations using chemotherapy for patients with small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 18:309-22. 2004
  101. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006